# The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome

**Authors:** Yawen Chen, Xiaoxiang Sun, Xuan Xia, Kaiqi Chen, Fang Zeng

PMC · DOI: 10.3389/fendo.2025.1722649 · Frontiers in Endocrinology · 2026-01-26

## TL;DR

This review explores the causes and treatment targets of polycystic ovary syndrome, a common hormonal disorder affecting women's health.

## Contribution

The paper identifies novel therapeutic targets like AGEs, SHBG, and miRNAs for PCOS treatment.

## Key findings

- PCOS involves complex mechanisms like oxidative stress, autophagy, and gut microbiota.
- AGEs, SHBG, and miRNAs are highlighted as promising therapeutic targets for PCOS.
- Combining lifestyle and pharmacological approaches is key for managing PCOS symptoms.

## Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder characterized by a high incidence rate and multiple complications, posing significant threats to women’s health and quality of life. The etiology of PCOS involves a complex interplay of genetic, metabolic, hormonal, immunological and environmental factors, though its precise mechanisms remain incompletely understood. This review explores the roles of oxidative stress, autophagy, ferroptosis, epigenetic modifications, post-translational modifications, chronic low-grade inflammation, and gut microbiota in the pathogenesis of PCOS. Current therapeutic strategies often combine lifestyle modifications with pharmacological interventions to address the multifaceted symptoms of PCOS. Drawing on the latest research, this review highlights advanced glycation end products (AGEs), sex hormone-binding globulin (SHBG), and microRNAs (miRNAs) as promising targets for PCOS prevention and treatment. Future research should focus on developing targeted drugs for these molecular pathways, offering new avenues for managing PCOS. This review will provide a scientific foundation for advancing PCOS treatment strategies.

Diagram illustrating the induction factors, mechanisms, and therapeutic targets of PCOS. The induction factors include genetic factors, insulin resistance, hormonal imbalance, immune system issues, and environmental lifestyle. Mechanisms encompass oxidative stress, autophagy, epigenetic modification, ferroptosis, protein phosphorylation, chronic low-grade inflammation, and gut microbiota. Therapeutic targets focus on oxidative stress inflammation, insulin resistance, hyperinsulinemia, excess androgen, steroidogenesis, and oocyte development.

## Linked entities

- **Diseases:** polycystic ovary syndrome (MONDO:0008487)

## Full-text entities

- **Genes:** SHBG (sex hormone binding globulin) [NCBI Gene 6462] {aka ABP, SBP, TEBG}
- **Diseases:** inflammation (MESH:D007249), PCOS (MESH:D011085), endocrine and metabolic disorder (MESH:D004700)
- **Chemicals:** advanced (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12883396/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12883396/full.md

## References

102 references — full list in the complete paper: https://tomesphere.com/paper/PMC12883396/full.md

---
Source: https://tomesphere.com/paper/PMC12883396